Comparative Pharmacology
Head-to-head clinical analysis: PARICALCITOL versus ROCALTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARICALCITOL versus ROCALTROL.
PARICALCITOL vs ROCALTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor (VDR) in target tissues, including the parathyroid glands, kidneys, and intestines. It selectively activates VDR to suppress parathyroid hormone (PTH) secretion, reduce parathyroid cell proliferation, and modulate calcium and phosphate homeostasis with lower calcemic and phosphatemic effects compared to calcitriol.
Calcitriol, the active form of vitamin D, binds to vitamin D receptors in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone mineralization.
0.04 to 0.1 mcg/kg intravenously bolus no more frequently than every other day during dialysis, or 1 to 4 mcg orally once daily.
Oral, 0.25 mcg once daily; may increase to 0.5 mcg once daily based on response. Typical adult dose is 0.25-0.5 mcg/day.
None Documented
None Documented
Clinical Note
moderateParicalcitol + Digoxin
"The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin."
Clinical Note
moderateParicalcitol + Hydrochlorothiazide
"Paricalcitol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateParicalcitol + Bendroflumethiazide
"Paricalcitol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateParicalcitol + Methyclothiazide
Terminal elimination half-life is approximately 5-7 hours in healthy subjects, but may be prolonged to 14-20 hours in patients with renal impairment.
Terminal elimination half-life is approximately 25–35 hours after oral administration. Clinical context: Once-weekly or thrice-weekly dosing achieves steady state in 1–2 weeks.
Primarily fecal (74%) via hepatobiliary excretion; renal elimination accounts for approximately 16% as unchanged drug.
Primarily biliary/fecal; approximately 50% of dose recovered in feces within 24 hours. Renal excretion accounts for <5% of unchanged drug.
Category C
Category C
Vitamin D Analog
Vitamin D Analog
"Paricalcitol may increase the hypercalcemic activities of Methyclothiazide."